These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27695908)

  • 1. Reply to Rahbar K et al.
    Yadav MP; Ballal S; Tripathi M; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):168-169. PubMed ID: 27695908
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Rahbar K; Bögemann M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):166-167. PubMed ID: 27699719
    [No Abstract]   [Full Text] [Related]  

  • 3. Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney.
    Norouzi G; Aghdam RA; Hashemifard H; Pirayesh E
    Clin Nucl Med; 2019 Jun; 44(6):483-484. PubMed ID: 30829871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of brain metastases of castration-resistant prostate cancer with
    Sathekge MM; Bruchertseifer F; Lawal IO; Vorster M; Knoesen O; Lengana T; Boshomane TG; Mokoala KK; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1756-1757. PubMed ID: 31115638
    [No Abstract]   [Full Text] [Related]  

  • 5. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617.
    Giesel FL; Cardinale J; Schäfer M; Neels O; Benešová M; Mier W; Haberkorn U; Kopka K; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1929-30. PubMed ID: 27342416
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
    Wei X; Schlenkhoff C; Sopora C; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Nov; 41(11):894-895. PubMed ID: 27607162
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Sathekge M; Knoesen O; Meckel M; Modiselle M; Vorster M; Marx S
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1099-1100. PubMed ID: 28255795
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Rahbar K; Ahmadzadehfar H; Boegemann M
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):513-514. PubMed ID: 29164300
    [No Abstract]   [Full Text] [Related]  

  • 9. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
    Fendler WP; Kratochwil C; Ahmadzadehfar H; Rahbar K; Baum RP; Schmidt M; Pfestroff A; Lützen U; Prasad V; Heinzel A; Heuschkel M; Ruf J; Bartenstein P; Krause BJ
    Nuklearmedizin; 2016 Jun; 55(3):123-8. PubMed ID: 27350005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
    Ahmadzadehfar H; Gaertner F; Lossin PS; Schwarz B; Essler M
    Clin Nucl Med; 2018 Aug; 43(8):609-610. PubMed ID: 29762244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer.
    Lawal IO; Bruchertseifer F; Vorster M; Morgenstern A; Sathekge MM
    Curr Opin Urol; 2020 Jan; 30(1):98-105. PubMed ID: 31644433
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
    Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
    Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
    Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
    Wei X; Schlenkhoff C; Schwarz B; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2017 Sep; 42(9):704-706. PubMed ID: 28719450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful handling of an accidental extravasation of 177Lu-PSMA-617 in the treatment of advanced prostate cancer.
    Jüptner M; Zuhayra M; Assam I; Lützen U
    Nuklearmedizin; 2018 Apr; 57(2):N10-N12. PubMed ID: 29590677
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials.
    Tunio M; Al Asiri M; Al Hadab A; Bayoumi Y
    Drug Des Devel Ther; 2015; 9():5291-9. PubMed ID: 26451085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy.
    Aryana K; Zarehparvar Moghadam S; Salek R; Divband G
    Clin Nucl Med; 2018 Apr; 43(4):273-275. PubMed ID: 29401146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks.
    Usmani S; Rasheed R; Al Kandari F; Marafi F; Naqvi SAR
    Clin Nucl Med; 2019 May; 44(5):401-403. PubMed ID: 30932973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.